News Scan for Apr 20, 2018

News brief

CDC expands E coli warning to all Yuma-grown romaine lettuce

The US Centers for Disease Control and Prevention (CDC) today expanded its warning to consumers to include all types of romaine lettuce from the Yuma, Ariz., growing area, based on new information from Alaska that sick people ate lettuce from whole heads of romaine.

In addition to advising against eating chopped romaine, which was originally tied to a multistate Escherichia coli O157:H7 outbreak, the CDC advises consumers to also avoid whole heads and hearts of romaine from the Yuma growing region. The CDC's initial warning also includes salads and salad mixes that contain chopped romaine.

Newly reported illnesses from Alaska will be included in the next case count update, the CDC said. For now, the outbreak total remains at 53 cases from 16 states.

In Alaska, state and local health officials interviewed sick people at a correctional facility about the food they ate and other exposures they had before symptoms began. Sick patients reported eating romaine lettuce, and trace-back investigations point to whole-head romaine sources from the Yuma, Ariz., growing area.

In earlier updates on the outbreak and the investigation, federal officials said the Yuma area generally supplies romaine to the United States during November through March each year. Produce industry groups have said nearly all of the romaine harvested and shipped now is from California areas not implicated in the outbreak. So far, no specific grower, supplier, distributor, or brand has been identified.
Apr 20 CDC outbreak update

 

End of flu season still sees pediatric deaths, high hospitalization rate

For the second week in a row, outpatient visits for influenza-like illness (ILI) fell below the national baseline of 2.2%, according to the latest flu surveillance update from the CDC, but flu deaths in children continue to be reported, and hospitalization rates have been record-breaking.

Despite the low levels of flu activity, the CDC noted 5 new pediatrics deaths, bringing the season's total to 156. This flu season has been one of the most deadly for kids in recent years, surpassing even the 2014-15 season, which saw 148 pediatric deaths.

Only 5 states are reporting widespread flu activity, down from the previous week's 7. The states are Connecticut, Delaware, Massachusetts, New York, and Rhode Island. Only Arizona experienced high ILI, with Alaska and South Dakota reporting moderate ILI.

Influenza B was the dominant strain last week, following the trend seen at the end of flu seasons. Of positive flu specimens gathered at clinical labs, 65.7% were influenza B. 

Overall hospitalizations are still high, at 103.7 lab-confirmed cases per 100,000 population, up from 101.6 the week before. In patients 65 and older it reached 446.4 per 100,000 population, up from 437.0 the week before. The vast majority of hospitalizations (73.8%) were due to infections with influenza A viruses.

In an accompanying summary of flu activity, the CDC said hospitalization rates this season have been record-breaking, exceeding end-of-season hospitalization rates for 2014-15, another season dominated by the H3N2 virus.
Apr 20 CDC FluView

 

Brazil reports more yellow fever infections and deaths

In a weekly update on its yellow fever outbreak, Brazil yesterday reported 30 more lab-confirmed cases and 11 more deaths from the disease, according to a statement from the country's health ministry. The new developments put the case total at 1,157 and the number of deaths to 342.

As of April 17, the ministry has received reports of 5,131 suspected cases and has ruled out 2,951, with 1,023 still under investigation. The three hardest hit states, where most of the illnesses have been reported, are Minas Gerais, Sao Paulo, and Rio de Janeiro.

Though the number of cases this season, which runs through Jun 30, has outpaced the previous one, the incidence this season is lower, because the mosquito-borne virus is circulating in metropolitan regions of the country with larger populations. Incidence this season is 3 per 100,000 population compared with 6.2 per 100,000 during the 2016-17 season.

Brazil has extended a yellow fever vaccination recommendation to the whole country with a goal of completing the campaign by April 2019, but uptake so far is well below the 95% target.
Apr 19 Brazilian MOH update

 

High-path avian flu outbreaks reported from four countries

Over the past week, four countries—China, South Africa, Taiwan, and Togo—have reported highly pathogenic avian influenza involving different strains, according to the latest notifications from the World Organization for Animal Health (OIE).

China's outbreak involved H7N9, which struck a layer farm in Ningxia province in the north. The outbreak began on Apr 3, killing 585 of 13,578 birds.

Meanwhile, South Africa reported several more H5N8 outbreaks involving both poultry and other types of birds. The two poultry outbreaks involved farms, one of them housing domestic ducks and quails, at locations in North West province. One event began on Mar 13, and the start date for the other was Apr 6. Taken together, the virus killed 584 of 41,012 birds. Also, the country reported four more H5N8 outbreaks involving wild birds in Western Cape province and one in hobby ducks at a location in Limpopo, its northernmost province. Between Jan 23 and Mar 22 the virus killed 14 wild birds and 11 of 85 hobby ducks.

In Taiwan, authorities reported four more H5N2 outbreaks, part of activity involving the virus that has been underway since 2015. All four events involved poultry farms with start dates ranging from Apr 2 to Apr 10. Species included native and breeding chickens. Deaths were reported in 7,242 of 62,935 birds.

Elsewhere, Togo reported an H5N1 outbreak at an agropastoral farm where layers, broilers, and swine were raised in Maritime region in the far south of the country. The event began on Mar 27, killing 3,629 of 5,001 susceptible birds. So far the source of the virus isn't known. Togo's last H5N1 outbreak was reported in October 2017.
Apr 19 OIE report on H7N9 in China
Apr 18 OIE report on non-poultry H5N8 in South Africa
Apr 18 OIE report on H5N8 in South African poultry
Apr 19 OIE report on H5N2 in Taiwan
Apr 18 OIE report on H5N1 in Togo

 

Study finds more support for wild ducks as H5N8 carriers

Wild ducks species may be driving the long-distance spread of highly pathogenic H5N8, according to researchers from the Netherlands who experimentally infected water birds and chickens to spot any virulence differences between infection from a H5N8 virus from 2014 and a H5N1 virus from 2005.

The team noted that the global spread of H5N8 to several continents in 2014 and 2015 raised questions about whether the virus was better adapted to wild birds than earlier H5 viruses. They reported their findings in an early online edition of Emerging Microbes and Infections.

The species they tested included Eurasian wigeons, common teals, mallards, and common pochards, all of them migratory birds that are abundant and play an important role in the ecology of avian influenza viruses.

H5N8 caused subclinical infections in all four of the species, but virus excretion was highest in Eurasian wigeons, providing the strongest evidence yet that they are long-distance carriers of the virus. More than half of pochards infected with the 2005 H5 virus had clinical illness. In chickens, the H5N8 virus caused systemic disease and high mortality, similar to the 2005 H5 virus.

The researchers concluded that a switch in virus excretion level, highest in wigeons for the 2014 virus, after being higher for pochards and mallard for the 2005 virus, and decreased clinical severity from the 2014 virus suggests that the earlier H5 viruses have adapted to wild waterfowl populations. They emphasized that their study only looked at a limited number of bird species and that others may be involved in H5 epidemiology, and more research is needed to explore additional contributors as well as spatial and temporal connections between migratory flyways.
Apr 18 Emerg Microb Infect abstract

Stewardship / Resistance Scan for Apr 20, 2018

News brief

Good news about UK 'super gonorrhea' case—but 2 new infections noted

UK officials today report good news on the outcome of the man treated for a highly resistant Neisseria gonorrhoeae infection, but they also note two similar cases in Australia.

In an update from Public Health England (PHE), Gwenda Hughes, PhD, head of the agency's Sexually Transmitted Infection Section, said, "We are pleased to report that the case of multi-drug resistant gonorrhoea has been successfully treated. Investigations have also revealed there has been no further spread of this infection within the UK. PHE continues to actively monitor and tackle the spread of antibiotic resistance in gonorrhoea and potential treatment failures."

The man had contracted gonorrhea after having sex with a woman in Southeast Asia. PHE first reported his case on Mar 28. In a full report on the case today, PHE experts said, "Efforts to contact the partner in south east Asia are ongoing."

Hughes said of the Australian infections, "Two similar cases have just been reported in Australia and serve as a timely reminder that we expect to see further cases of multi-drug resistant gonorrhoea in the future. These cases will be challenging for healthcare professionals to manage."

The full report added, "Two cases of gonorrhoea with resistance to ceftriaxone, azithromycin, ciprofloxacin, penicillin, and tetracycline have subsequently been reported in Australia: one had had sex recently in south east Asia; the other case had no recent overseas travel."
Apr 20 PHE update
Apr 20 full PHE report
Mar 28 CIDRAP News story on the UK case

 

Removing penicillin allergy label from kids saves antibiotics, money

A study today by US researchers reveals that children with low-risk penicillin allergy symptoms whose test results were negative for penicillin allergy tolerated a penicillin challenge without a severe allergic reaction, and the cost savings of removing the penicillin allergy label from these patients was substantial.

As detailed in Pediatrics, the investigators had previously performed three-tier penicillin allergy testing on children with low-risk symptoms, and all of them tolerated a penicillin challenge without an allergic reaction. They hypothesized that the children would have no serious allergic reactions after re-exposure to penicillin.

In the new study, the researchers conducted a case series on 100 children whose tests were negative for penicillin allergy. In the year after they were tested for penicillin allergy, 36 of the kids received a total of 46 prescriptions, 26 of which (58%) were for penicillin derivatives. None of these children had an adverse reaction; 1 developed a rash.

The team determined that "delabeling" the children as no longer penicillin allergic saved $1,368 per patient, with an additional cost avoidance of $1,812, for a potential total cost saving for the pediatric emergency department of $192,223.

The authors conclude, "Delabeling children changed prescription behavior and led to actual health care savings."
Apr 20 Pediatrics abstract

 

Colombia reports 123 recent Candida auris cases

A report today in Morbidity and Mortality Weekly Report (MMWR) details 123 newly identified Candida auris infections in Colombia, noting that the pathogen has been present there since at least 2015 and that case counts are increasing.

After the US Centers for Disease Control and Prevention issued an alert in 2016 about the worrisome fungal infection, Colombian scientists re-investigated 45 isolates from 2013 through 2016 that had been classified as C haemolunii, which is often misidentified. Upon retesting, all of them proved to be C auris, with the most recent being from 2015, and Colombian officials released a clinical alert for heightened awareness of the pathogen.

After this alert, the Colombian national health institute received an additional 78 C auris isolates from 24 healthcare facilities in nine states, for a total of 123 confirmed cases. Antifungal susceptibility testing on 93 of the isolates showed that 28 (30%) were resistant to fluconazole, 20 (22%) to amphotericin B, 1 (1%) to anidulafungin, and 1 (1%) to both amphotericin B and anidulafungin.

The authors conclude, "The number of reported cases likely does not reflect the true number of infected and colonized persons because of underreporting and underdiagnosis, as well as misdiagnosis as other yeast species."
Apr 20 MMWR report

ASP Scan (Weekly) for Apr 20, 2018

News brief

Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans

Good news about UK 'super gonorrhea' case—but 2 new infections noted

UK officials today report good news on the outcome of the man treated for a highly resistant Neisseria gonorrhoeae infection, but they also note two similar cases in Australia.

In an update from Public Health England (PHE), Gwenda Hughes, PhD, head of the agency's Sexually Transmitted Infection Section, said, "We are pleased to report that the case of multi-drug resistant gonorrhoea has been successfully treated. Investigations have also revealed there has been no further spread of this infection within the UK. PHE continues to actively monitor and tackle the spread of antibiotic resistance in gonorrhoea and potential treatment failures."

The man had contracted gonorrhea after having sex with a woman in Southeast Asia. PHE first reported his case on Mar 28. In a full report on the case today, PHE experts said, "Efforts to contact the partner in south east Asia are ongoing."

Hughes said of the Australian infections, "Two similar cases have just been reported in Australia and serve as a timely reminder that we expect to see further cases of multi-drug resistant gonorrhoea in the future. These cases will be challenging for healthcare professionals to manage."

The full report added, "Two cases of gonorrhoea with resistance to ceftriaxone, azithromycin, ciprofloxacin, penicillin, and tetracycline have subsequently been reported in Australia: one had had sex recently in south east Asia; the other case had no recent overseas travel."
Apr 20 PHE update
Apr 20 full PHE report
Mar 28 CIDRAP News story on the UK case

 

Removing penicillin allergy label from kids saves antibiotics, money

A study today by US researchers reveals that children with low-risk penicillin allergy symptoms whose test results were negative for penicillin allergy tolerated a penicillin challenge without a severe allergic reaction, and the cost savings of removing the penicillin allergy label from these patients was substantial.

As detailed in Pediatrics, the investigators had previously performed three-tier penicillin allergy testing on children with low-risk symptoms, and all of them tolerated a penicillin challenge without an allergic reaction. They hypothesized that the children would have no serious allergic reactions after re-exposure to penicillin.

In the new study, the researchers conducted a case series on 100 children whose tests were negative for penicillin allergy. In the year after they were tested for penicillin allergy, 36 of the kids received a total of 46 prescriptions, 26 of which (58%) were for penicillin derivatives. None of these children had an adverse reaction; 1 developed a rash.

The team determined that "delabeling" the children as no longer penicillin allergic saved $1,368 per patient, with an additional cost avoidance of $1,812, for a potential total cost saving for the pediatric emergency department of $192,223.

The authors conclude, "Delabeling children changed prescription behavior and led to actual health care savings."
Apr 20 Pediatrics abstract

 

Colombia reports 123 recent Candida auris cases

A report today in Morbidity and Mortality Weekly Report (MMWR) details 123 newly identified Candida auris infections in Colombia, noting that the pathogen has been present there since at least 2015 and that case counts are increasing.

After the US Centers for Disease Control and Prevention issued an alert in 2016 about the worrisome fungal infection, Colombian scientists re-investigated 45 isolates from 2013 through 2016 that had been classified as C haemolunii, which is often misidentified. Upon retesting, all of them proved to be C auris, with the most recent being from 2015, and Colombian officials released a clinical alert for heightened awareness of the pathogen.

After this alert, the Colombian national health institute received an additional 78 C auris isolates from 24 healthcare facilities in nine states, for a total of 123 confirmed cases. Antifungal susceptibility testing on 93 of the isolates showed that 28 (30%) were resistant to fluconazole, 20 (22%) to amphotericin B, 1 (1%) to anidulafungin, and 1 (1%) to both amphotericin B and anidulafungin.

The authors conclude, "The number of reported cases likely does not reflect the true number of infected and colonized persons because of underreporting and underdiagnosis, as well as misdiagnosis as other yeast species."
Apr 20 MMWR report

 

New colistin resistance gene identified in Chinese poultry

Originally published by CIDRAP News Apr 18

Chinese scientists have discovered another colistin resistance gene in bacteria isolated from chickens, according to a study yesterday in the Journal of Antimicrobial Chemotherapy.

The plasmid-mediated gene was detected among 183 Klebsiella pneumoniae isolates collected from 2010 to 2015 from chickens in 13 Chinese provinces. Of the 10 colistin-resistant isolates detected, polymerase chain reaction (PCR) screening identified the MCR-1 gene in seven; the other three were negative for known colistin resistance genes. Whole-genome sequencing of one of the isolates identified a novel colistin resistance gene, dubbed MCR-7.1, in an Inc12-type plasmid that also harbored the blaCTX-M-55 beta-lactam resistance gene. Subsequent PCR screening showed that the other two K pneumoniae isolates also carried the MCR-7.1 gene. Conjugation experiments showed that the plasmid can successfully be transferred from K pneumoniae to E coli.

The researchers report that the amino acid sequence of MCR-7.1 shares a 70% similarity with MCR-3, and that the gene may have originated from Aeromonas species. They recommend screening bacteria in animals, humans, and the environment to understand dissemination of the gene throughout the world.

Before this discovery, various research groups had described MCR-1 though MCR-6 genes.
Apr 17 J Antimicrob Chemother abstract

 

Chinese study finds low MCR-1 prevalence in clinical isolates

Originally published by CIDRAP News Apr 18

In another study yesterday in the Journal of Antimicrobial Chemotherapy, a separate group of Chinese researchers report that the prevalence of MCR-1 among clinical isolates of E coli and K pneumoniae is low, but that MCR-1–positive E coli strains were highly resistant to other antibiotics.

The researchers from Peking University First Hospital and China Agricultural University analyzed 6,424 clinical E coli and K pneumoniae isolates collected from patients in Chinese hospitals from 2007 through 2016. Overall, 34 E coli isolates and 5 K pneumoniae isolates were positive for MCR-1. Multilocus sequence typing revealed high clonal diversity, identifying three different sequence types (STs) among the K pneumoniae isolates, and 28 distinct STs among the E coli isolates.

All the MCR-1–positive isolates were resistant to colistin, and MCR-1–positive E coli also displayed high levels of resistance to tetracycline, ciprofloxacin, and some cephalosporins. In addition, the researchers noted extremely significant difference in the rates of resistance to piperacillin, amikacin, nitrofurantoin, and fosfomycin between MCR-1–negative E coli and MCR-1–positive E coli. This finding, they suggest, indicates that infections caused by MCR-1–postive E coli strains should be treated differently than those caused by MCR-1–negative E coli.

All but six of the MCR-1–positive isolates (84.6%) were also extended-spectrum beta-lactamase producers, and 36 of the 39 (92.3%) were multidrug-resistant.
Apr 17 J Antimicrob Chemother abstract

 

High level of Shiga toxin-producing E coli found in Iranian dairy products

Originally published by CIDRAP News Apr 18

Iranian researchers report a high prevalence of Shiga toxin–producing E coli (STEC) with high levels of antibiotic resistance in raw milk and traditional dairy products.

In the study, published in Antimicrobial Resistance and Infection Control, the researchers collected 600 raw milk and traditional dairy product samples from producers in Isfahan province from March 2015 to March 2016, then cultured all the samples and isolated E coli strains. PCR was used to identify virulence factors, O-serogroups, and antibiotic resistance genes, and antibiotic resistance patterns were determined by disk diffusion.

Of the 600 samples tested, 181 (30.16%) were positive for E coli strains, with cheese (80%) and raw buffalo milk (50%) having the highest prevalence. Sixty-four of the E coli isolates were determined to be STEC strains, with O157 (43.75%) and O26 (37.5%) the most frequently identified serogroups.

Stx, eae, and ehly were the most commonly identified virulence factors in the STEC strains, and Aac(3)-IV, CITM, and tetA were the most commonly detected resistance genes. STEC strains harbored the highest prevalence of resistance against ampicillin (100%), gentamicin (100%), and tetracyclines (96.87%), and all of the STEC strains were resistant to at least one antibiotic. In addition, 43.75% were resistant to seven or more antibiotics.

The authors suggest that Iranian ranchers' use of their hands and traditional milking equipment could partially explain the high prevalence of E coli and STEC strains, as could keeping raw milk samples at temperatures that allow bacteria to proliferate and survive and using unpasteurized milk for production of dairy products. They also cite illegal and inaccurate use of antibiotics in veterinary medicine as the main reason for the high prevalence of antibiotic resistance in the STEC strains.
Apr 16 Antimicrob Resist Infect Control study

 

Paper describes One Health strategy for stewardship in South Africa

Originally published by CIDRAP News Apr 17

A commentary yesterday in The Lancet Infectious Diseases outlines the efforts by South Africa to promote stewardship of the last-resort antibiotic colistin, an approach the authors say is pertinent to all shared-use antibiotics.

In the paper, Marc Mendelson, PhD, and colleagues describe how South Africa has responded to the threat of losing colistin as a treatment for multidrug-resistant infections in humans through a One Health platform that promotes stewardship of the drug across human, animal, and environmental health. The response was prompted by the discovery of the mobile colistin-resistance gene MCR-1 in Escherichia coli in South African poultry and the identification of MCR-1-induced colistin resistance in South African patients.

The paper highlights the work of the Colistin Working Group, which was convened by the South African Medicines Control Council and first met in April 2016. Using data on colistin consumption and resistance levels in humans and animals in South Africa, along with a report on colistin from the European Medicines Agency, the group issued detailed recommendations on steps the South African government could take to mitigate colistin resistance. Among the recommendations was that colistin no longer be used in food-producing animals.

Since issuing that recommendations, the group has expanded to include additional stakeholders from various government departments and formed a One Health Stewardship Sub-Committee to take the work further.

"We believe that our approach of convening intersectoral stakeholders across the One Health platform to develop a national strategy for the stewardship of antibiotics provides valuable lessons for future work in South Africa, and that such a method could be useful in other countries," the authors write.
Apr 16 Lancet Infect Dis personal view

 

Algorithm helps identify antimicrobial peptide with therapeutic potential

Originally published by CIDRAP News Apr 16

An international team of scientists reports today on the use of a computational approach to develop an artificial antimicrobial peptide with the potential to treat gram-negative bacteria.

In a paper published in Nature Communications, researchers from the Massachusetts Institute of Technology (MIT) and the Catholic University of Brasilia describe their approach, which relies on a computer algorithm to generate and evaluate antimicrobial peptide sequences with the greatest potential for antimicrobial activity. Using as a template the plant peptide Pg-AMP1—which is found in the seeds of the guava plant but has only weak antimicrobial activity—the scientists generated 100 candidates and then synthesized them to test against bacteria grown in the lab.

The most promising of these candidates was guavinin 2, which was highly active against E coli and Acinetobacter baumannii, with limited activity against K pneumoniae and modest killing activity toward gram-positive bacteria. When tested in mice with a skin infection caused by Pseudomonas aeruginosa, guavanin 2 significantly reduced the bacterial count.

The scientists say they will continue developing guavanin 2 for use in humans and will use the algorithm to seek out other antimicrobial peptides.

"We can use computers to do a lot of the work for us, as a discovery tool of new antimicrobial peptide sequences," study co-author Cesar de la Fuente-Nunez, PhD, said in an MIT press release. "This computational approach is much more cost-effective and much more time-effective."
Apr 16 Nat Commun study 
Apr 16 MIT press release

This week's top reads